Eone Diagnomics Genome Center Co.Ltd. announced a private placement of series 9 unregistered unguaranteed private convertible bonds for gross proceeds of KRW 6,000,000,000 on April 22, 2022. The transaction will involve participation from new investor Shinhan Financial Investment Co., Ltd. for KRW 1,000,000,000, Fund 2 of Samsung Securities Co., Ltd. for KRW 300,000,000, Fund 3 of Samsung Securities Co., Ltd. for KRW 700,000,000, fund 6 of Samsung Securities Co., Ltd. for KRW 1,000,000,000, Mirae Asset Securities Co., Ltd. for KRW 1,000,000,000, KB Securities Co., Ltd. for KRW 1,000,000,000, Jace Investment Advisory Co., Ltd. for KRW 1,000,000,000. The bonds will mature on April 27, 2027.

The bonds will be issued at par and carry no coupon rate and yield to maturity. The bonds are fully convertible into 1,343,183 common shares for 1.57% stake in the company at KRW 4,467 per share. The conversion period will be from May 27, 2022 to March 27, 2027.

The payment date is April 27, 2022. The transaction has been approved by the board of directors. The securities are subject to 1 year hold period.